DE69114782T2 - Intravaskulär embolisierendes Mittel mit Gehalt an einem die Angiogenesis hemmenden Stoff. - Google Patents

Intravaskulär embolisierendes Mittel mit Gehalt an einem die Angiogenesis hemmenden Stoff.

Info

Publication number
DE69114782T2
DE69114782T2 DE69114782T DE69114782T DE69114782T2 DE 69114782 T2 DE69114782 T2 DE 69114782T2 DE 69114782 T DE69114782 T DE 69114782T DE 69114782 T DE69114782 T DE 69114782T DE 69114782 T2 DE69114782 T2 DE 69114782T2
Authority
DE
Germany
Prior art keywords
agent containing
intravascular embolizing
angiogenesis inhibitor
agent
embolizing agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69114782T
Other languages
English (en)
Other versions
DE69114782D1 (de
Inventor
Hiroaki Okada
Shigeru Kamei
Toshio Yoshioka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of DE69114782D1 publication Critical patent/DE69114782D1/de
Publication of DE69114782T2 publication Critical patent/DE69114782T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
DE69114782T 1990-08-08 1991-08-06 Intravaskulär embolisierendes Mittel mit Gehalt an einem die Angiogenesis hemmenden Stoff. Expired - Fee Related DE69114782T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP21062290 1990-08-08
JP632391 1991-01-23

Publications (2)

Publication Number Publication Date
DE69114782D1 DE69114782D1 (de) 1996-01-04
DE69114782T2 true DE69114782T2 (de) 1996-04-18

Family

ID=26340431

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69114782T Expired - Fee Related DE69114782T2 (de) 1990-08-08 1991-08-06 Intravaskulär embolisierendes Mittel mit Gehalt an einem die Angiogenesis hemmenden Stoff.

Country Status (6)

Country Link
US (1) US5202352A (de)
EP (1) EP0470569B1 (de)
JP (1) JP2001039869A (de)
AT (1) ATE130517T1 (de)
CA (1) CA2048544C (de)
DE (1) DE69114782T2 (de)

Families Citing this family (176)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
ATE153854T1 (de) * 1992-12-16 1997-06-15 Takeda Chemical Industries Ltd Stabile pharmazeutische zubereitung mit fumagillolderivaten
NZ511762A (en) * 1993-07-19 2003-09-26 Univ British Columbia Anti-angiogenic compositions and methods of use
US5716981A (en) * 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
AU771815B2 (en) * 1993-07-19 2004-04-01 Angiotech Pharmaceuticals, Inc. Anti-angiogenic compositions and methods of use
US20030203976A1 (en) 1993-07-19 2003-10-30 William L. Hunter Anti-angiogenic compositions and methods of use
AU728873B2 (en) * 1993-07-19 2001-01-18 Angiotech Pharmaceuticals, Inc. Anti-angiogenic compositions and methods of use
DE69417169T2 (de) * 1993-09-24 1999-07-22 Takeda Chemical Industries Ltd Antineoplastische pharmazeutische Zusammensetzung enthaltend ein Fumagillolderivat und einen Platinkomplex
US5753230A (en) 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US6500924B1 (en) 1996-05-31 2002-12-31 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
JP2535785B2 (ja) * 1994-06-03 1996-09-18 工業技術院長 血管塞栓剤
US6558798B2 (en) 1995-02-22 2003-05-06 Scimed Life Systems, Inc. Hydrophilic coating and substrates coated therewith having enhanced durability and lubricity
ES2194110T3 (es) * 1995-07-27 2003-11-16 Micro Therapeutics Inc Nuevas composiciones embolizantes.
US5667767A (en) * 1995-07-27 1997-09-16 Micro Therapeutics, Inc. Compositions for use in embolizing blood vessels
US5580568A (en) * 1995-07-27 1996-12-03 Micro Therapeutics, Inc. Cellulose diacetate compositions for use in embolizing blood vessels
KR970069028A (ko) * 1996-04-01 1997-11-07 김은영 화학색전용 에멀젼의 제조방법
AU2745497A (en) 1996-05-31 1998-01-05 Micro Therapeutics, Inc. Compositions for use in embolizing blood vessels
US5695480A (en) * 1996-07-29 1997-12-09 Micro Therapeutics, Inc. Embolizing compositions
US5925683A (en) * 1996-10-17 1999-07-20 Target Therapeutics, Inc. Liquid embolic agents
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US5837283A (en) 1997-03-12 1998-11-17 The Regents Of The University Of California Cationic lipid compositions targeting angiogenic endothelial cells
US7112338B2 (en) * 1997-03-12 2006-09-26 The Regents Of The University Of California Cationic liposome delivery of taxanes to angiogenic blood vessels
AU7068698A (en) * 1997-04-24 1998-11-13 General Hospital Corporation, The Embolus therapy using insoluble microparticles or vesicles containing contrast agents
EP0927558A1 (de) * 1997-12-31 1999-07-07 Nycomed Imaging As Tenside enthaltendes Mittel zum Embolisieren
GB9727518D0 (en) * 1997-12-31 1998-02-25 Nycomed Imaging As Use
US6660301B1 (en) * 1998-03-06 2003-12-09 Biosphere Medical, Inc. Injectable microspheres for dermal augmentation and tissue bulking
US6241762B1 (en) 1998-03-30 2001-06-05 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US7208010B2 (en) 2000-10-16 2007-04-24 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US20040254635A1 (en) 1998-03-30 2004-12-16 Shanley John F. Expandable medical device for delivery of beneficial agent
FR2784580B1 (fr) * 1998-10-16 2004-06-25 Biosepra Inc Microspheres de polyvinyl-alcool et procedes de fabrication de celles-ci
US6293967B1 (en) 1998-10-29 2001-09-25 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US20050281821A1 (en) * 1999-01-06 2005-12-22 Flavia Pernasetti Method and composition for angiogenesis inhibition
US6120847A (en) * 1999-01-08 2000-09-19 Scimed Life Systems, Inc. Surface treatment method for stent coating
US6419692B1 (en) 1999-02-03 2002-07-16 Scimed Life Systems, Inc. Surface protection method for stents and balloon catheters for drug delivery
US6156373A (en) * 1999-05-03 2000-12-05 Scimed Life Systems, Inc. Medical device coating methods and devices
CA2371321C (en) 1999-05-21 2008-12-23 Micro Therapeutics, Inc. Novel high viscosity embolizing compositions
US6258121B1 (en) 1999-07-02 2001-07-10 Scimed Life Systems, Inc. Stent coating
AU6058000A (en) * 1999-07-12 2001-01-30 Scimed Life Systems, Inc. Liquid based vaso-occlusive compositions
CZ2002850A3 (cs) * 1999-09-09 2003-04-16 The Regents Of The University Of California Kationtový liposom a použití kationtového liposomového prostředku
CA2395136A1 (en) 1999-12-22 2001-06-28 The Scripps Research Institute Angiogenesis and vascular permeability modulators and inhibitors
EP1263803B1 (de) 2000-03-13 2007-09-19 BioCure, Inc. Embolische zusammensetzungen
WO2001068722A1 (en) * 2000-03-13 2001-09-20 Biocure, Inc. Hydrogel biomedical articles
US6436424B1 (en) 2000-03-20 2002-08-20 Biosphere Medical, Inc. Injectable and swellable microspheres for dermal augmentation
EP1274472A2 (de) 2000-03-20 2003-01-15 Biosphere Medical, Inc. Injizierbare und schwellfähige mikrokügelchen zur gewebeverstärkung
US7338657B2 (en) * 2001-03-15 2008-03-04 Biosphere Medical, Inc. Injectable microspheres for tissue construction
CN101708165A (zh) * 2000-03-24 2010-05-19 生物领域医疗公司 用于主动栓塞术的微球体
US20030212022A1 (en) * 2001-03-23 2003-11-13 Jean-Marie Vogel Compositions and methods for gene therapy
US6355275B1 (en) 2000-06-23 2002-03-12 Carbon Medical Technologies, Inc. Embolization using carbon coated microparticles
US6394965B1 (en) 2000-08-15 2002-05-28 Carbon Medical Technologies, Inc. Tissue marking using biocompatible microparticles
JP4817088B2 (ja) * 2000-10-10 2011-11-16 株式会社林原生物化学研究所 塞栓材料
KR100819895B1 (ko) 2000-10-16 2008-04-07 코너 메드시스템즈 인코포레이티드 약제 전달용 팽창 가능한 의료 장치
BR0114713A (pt) * 2000-10-16 2004-01-13 Neopharm Inc Formulação lipossÈmica de mitoxantrona
US6764507B2 (en) 2000-10-16 2004-07-20 Conor Medsystems, Inc. Expandable medical device with improved spatial distribution
US6648911B1 (en) 2000-11-20 2003-11-18 Avantec Vascular Corporation Method and device for the treatment of vulnerable tissue site
US20040073294A1 (en) 2002-09-20 2004-04-15 Conor Medsystems, Inc. Method and apparatus for loading a beneficial agent into an expandable medical device
US6815426B2 (en) * 2001-02-16 2004-11-09 E. I. Du Pont De Nemours And Company Angiogenesis-inhibitory tripeptides, compositions and their methods of use
US20040185101A1 (en) * 2001-03-27 2004-09-23 Macromed, Incorporated. Biodegradable triblock copolymers as solubilizing agents for drugs and method of use thereof
EP1393069A1 (de) * 2001-05-24 2004-03-03 The University Of Florida Verfahren und vorrichtung zur rauchaussetzungfeststellung
US7365167B2 (en) * 2001-11-26 2008-04-29 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US7390885B2 (en) * 2001-11-26 2008-06-24 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US7462366B2 (en) * 2002-03-29 2008-12-09 Boston Scientific Scimed, Inc. Drug delivery particle
US7131997B2 (en) * 2002-03-29 2006-11-07 Scimed Life Systems, Inc. Tissue treatment
US7094369B2 (en) * 2002-03-29 2006-08-22 Scimed Life Systems, Inc. Processes for manufacturing polymeric microspheres
US7053134B2 (en) * 2002-04-04 2006-05-30 Scimed Life Systems, Inc. Forming a chemically cross-linked particle of a desired shape and diameter
US7341716B2 (en) * 2002-04-12 2008-03-11 Boston Scientific Scimed, Inc. Occlusive composition
US7670623B2 (en) * 2002-05-31 2010-03-02 Materials Modification, Inc. Hemostatic composition
US7649023B2 (en) * 2002-06-11 2010-01-19 Novartis Ag Biodegradable block copolymeric compositions for drug delivery
EP1511522B1 (de) 2002-06-12 2011-08-10 Boston Scientific Limited Quellstoffe
US7097850B2 (en) 2002-06-18 2006-08-29 Surmodics, Inc. Bioactive agent release coating and controlled humidity method
JP4393098B2 (ja) * 2002-06-21 2010-01-06 独立行政法人科学技術振興機構 アンサマイシン系抗生物質の新規用途及び新規血管新生抑制物質のスクリーニング方法
DE20320989U1 (de) * 2002-07-12 2005-09-15 Mycrona Ges Fuer Innovative Me Vorrichtung zur Bestimmung der Ist-Position einer Struktur eines Untersuchungsobjektes in einem Koordinatensystem
US7842377B2 (en) 2003-08-08 2010-11-30 Boston Scientific Scimed, Inc. Porous polymeric particle comprising polyvinyl alcohol and having interior to surface porosity-gradient
US7449236B2 (en) * 2002-08-09 2008-11-11 Boston Scientific Scimed, Inc. Porous polymeric particle comprising polyvinyl alcohol and having interior to surface porosity-gradient
US8012454B2 (en) 2002-08-30 2011-09-06 Boston Scientific Scimed, Inc. Embolization
US8071569B2 (en) * 2002-09-20 2011-12-06 Mousa Shaker A Oxidized heparin fractions and their use in inhibiting angiogenesis
US20040156781A1 (en) * 2002-10-15 2004-08-12 Porter Christopher H. Polymeric materials for site specific delivery to the body
US7588825B2 (en) * 2002-10-23 2009-09-15 Boston Scientific Scimed, Inc. Embolic compositions
US7883490B2 (en) 2002-10-23 2011-02-08 Boston Scientific Scimed, Inc. Mixing and delivery of therapeutic compositions
US7560160B2 (en) * 2002-11-25 2009-07-14 Materials Modification, Inc. Multifunctional particulate material, fluid, and composition
US20040161466A1 (en) 2003-02-14 2004-08-19 Biocompatibles Uk Limited Chemoembolisation
US7662783B2 (en) * 2003-02-20 2010-02-16 New York University CLK-peptide and SLK-peptide
US7601694B2 (en) * 2003-02-20 2009-10-13 New York University CLK-peptide and SLK-peptide
US7007972B1 (en) 2003-03-10 2006-03-07 Materials Modification, Inc. Method and airbag inflation apparatus employing magnetic fluid
US7387998B2 (en) * 2003-03-28 2008-06-17 New York University STQ peptides
US6982501B1 (en) 2003-05-19 2006-01-03 Materials Modification, Inc. Magnetic fluid power generator device and method for generating power
US7200956B1 (en) 2003-07-23 2007-04-10 Materials Modification, Inc. Magnetic fluid cushioning device for a footwear or shoe
US7976823B2 (en) 2003-08-29 2011-07-12 Boston Scientific Scimed, Inc. Ferromagnetic particles and methods
US7785653B2 (en) 2003-09-22 2010-08-31 Innovational Holdings Llc Method and apparatus for loading a beneficial agent into an expandable medical device
US7448389B1 (en) 2003-10-10 2008-11-11 Materials Modification, Inc. Method and kit for inducing hypoxia in tumors through the use of a magnetic fluid
US20050090804A1 (en) * 2003-10-22 2005-04-28 Trivascular, Inc. Endoluminal prosthesis endoleak management
US7901770B2 (en) * 2003-11-04 2011-03-08 Boston Scientific Scimed, Inc. Embolic compositions
CA2554537A1 (en) * 2004-02-17 2005-09-01 Cancervax Corporation Method and composition for angiogenesis inhibition
US7736671B2 (en) * 2004-03-02 2010-06-15 Boston Scientific Scimed, Inc. Embolization
AU2005224081B2 (en) 2004-03-12 2011-06-30 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
US8173176B2 (en) 2004-03-30 2012-05-08 Boston Scientific Scimed, Inc. Embolization
US20050238870A1 (en) * 2004-04-22 2005-10-27 Marcia Buiser Embolization
US7311861B2 (en) 2004-06-01 2007-12-25 Boston Scientific Scimed, Inc. Embolization
ES2433663T3 (es) 2004-06-15 2013-12-12 Polymedix, Inc. Compuestos policatiónicos y usos de los mismos
US7973134B2 (en) * 2004-07-07 2011-07-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways
WO2006034455A2 (en) 2004-09-23 2006-03-30 Vasgene Therapeutics, Inc. Polipeptide compounds for inhibiting angiogenesis and tumor growth
US7935790B2 (en) * 2004-10-04 2011-05-03 Cell Singaling Technology, Inc. Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways
US8425550B2 (en) 2004-12-01 2013-04-23 Boston Scientific Scimed, Inc. Embolic coils
US7807789B2 (en) * 2004-12-21 2010-10-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in EGFR-signaling pathways
US7727555B2 (en) * 2005-03-02 2010-06-01 Boston Scientific Scimed, Inc. Particles
US7858183B2 (en) 2005-03-02 2010-12-28 Boston Scientific Scimed, Inc. Particles
US20060240002A1 (en) * 2005-03-11 2006-10-26 Brooks Peter C Methods of inhibiting angiogenesis-dependent conditions mediated by cryptic epitopes of extracellular matrix components
US20060216236A1 (en) * 2005-03-11 2006-09-28 Brooks Peter C Methods of inhibiting alphavBeta3-mediated angiogenesis and tumor development
US20060216237A1 (en) * 2005-03-11 2006-09-28 Brooks Peter C Inhibition of angiogenesis and tumor development by IGFBP-4
US20090099340A1 (en) * 2007-10-12 2009-04-16 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
US7963287B2 (en) * 2005-04-28 2011-06-21 Boston Scientific Scimed, Inc. Tissue-treatment methods
EP2484344B1 (de) 2005-05-09 2016-02-10 Biosphere Medical, S.A. Zusammensetzungen und Verfahren zum Verwenden von Mikrokügelchen und nicht ionischen Kontrastmitteln
US20070004973A1 (en) * 2005-06-15 2007-01-04 Tan Sharon M L Tissue treatment methods
US9463426B2 (en) 2005-06-24 2016-10-11 Boston Scientific Scimed, Inc. Methods and systems for coating particles
AU2006283174A1 (en) * 2005-08-24 2007-03-01 Cell-Matrix, Inc. Combination therapies for inhibiting integrin-extracellular matrix interactions
WO2007027906A2 (en) * 2005-08-31 2007-03-08 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
US20100151495A9 (en) * 2005-08-31 2010-06-17 Cell Signaling Technolgy, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
US8007509B2 (en) * 2005-10-12 2011-08-30 Boston Scientific Scimed, Inc. Coil assemblies, components and methods
US20070083219A1 (en) * 2005-10-12 2007-04-12 Buiser Marcia S Embolic coil introducer sheath locking mechanisms
US8152839B2 (en) * 2005-12-19 2012-04-10 Boston Scientific Scimed, Inc. Embolic coils
US8101197B2 (en) 2005-12-19 2012-01-24 Stryker Corporation Forming coils
US20070142859A1 (en) * 2005-12-19 2007-06-21 Boston Scientific Scimed, Inc. Embolic coils
US7947368B2 (en) 2005-12-21 2011-05-24 Boston Scientific Scimed, Inc. Block copolymer particles
US20070142560A1 (en) * 2005-12-21 2007-06-21 Young-Ho Song Block copolymer particles
US7501179B2 (en) * 2005-12-21 2009-03-10 Boston Scientific Scimed, Inc. Block copolymer particles
US8075884B2 (en) 2006-01-12 2011-12-13 Alexion Pharmaceuticals, Inc. Antibodies to OX-2/CD200 and uses thereof
EP2368581B1 (de) * 2006-01-30 2018-08-29 Biosphere Medical, Inc. Poröse intravaskuläre Embolisierungspartikel und zugehörige Verfahren
WO2007090127A2 (en) * 2006-01-30 2007-08-09 Surgica Corporation Compressible intravascular embolization particles and related methods and delivery systems
WO2007127335A2 (en) * 2006-04-27 2007-11-08 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in atm and atr kinase signaling pathways
US20070299461A1 (en) * 2006-06-21 2007-12-27 Boston Scientific Scimed, Inc. Embolic coils and related components, systems, and methods
US7939636B2 (en) * 2006-08-11 2011-05-10 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in c-Src signaling pathways
US20090258442A1 (en) * 2006-08-31 2009-10-15 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
US8414927B2 (en) 2006-11-03 2013-04-09 Boston Scientific Scimed, Inc. Cross-linked polymer particles
EP2094169A4 (de) * 2006-12-11 2016-05-04 Pluromed Inc Hämostase bei durchbluteten organen
US20080145658A1 (en) * 2006-12-15 2008-06-19 Boston Scientific Scimed, Inc. Freeze Thaw Methods For Making Polymer Particles
RU2473362C2 (ru) 2007-02-01 2013-01-27 Акселерон Фарма Инк. АНТАГОНИСТЫ АКТИВИНА-ActRIIa-Fc И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ
EP1972639A3 (de) 2007-03-07 2008-12-03 Cell Signaling Technology, Inc. Reagenzien zur Erkennung von Proteinphosphorylierung in Karzinom-Signalwegen
EP1975184A3 (de) 2007-03-26 2008-11-26 Cell Signaling Technology, Inc. Serin- oder Threonin-Phosphorylationsorte
US20080238709A1 (en) * 2007-03-28 2008-10-02 Faramarz Vaziri One-way communication apparatus with dynamic key generation
US9642693B2 (en) * 2007-04-13 2017-05-09 W. L. Gore & Associates, Inc. Medical apparatus and method of making the same
US9717584B2 (en) * 2007-04-13 2017-08-01 W. L. Gore & Associates, Inc. Medical apparatus and method of making the same
US20080255678A1 (en) * 2007-04-13 2008-10-16 Cully Edward H Medical apparatus and method of making the same
EP1983003A3 (de) 2007-04-19 2009-03-11 Peter Hornbeck Tyrosinphosphorylationsstellen und spezifische Antikörper
US7977462B2 (en) 2007-04-19 2011-07-12 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
EP1983002A3 (de) 2007-04-19 2009-03-11 Peter Hornbeck Tyrosinphosphorylations-Stellen und spezifische Antikörper
US20090053831A1 (en) 2007-05-01 2009-02-26 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
CN107412734A (zh) 2007-09-18 2017-12-01 阿塞勒隆制药公司 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途
US8226701B2 (en) 2007-09-26 2012-07-24 Trivascular, Inc. Stent and delivery system for deployment thereof
US8066755B2 (en) 2007-09-26 2011-11-29 Trivascular, Inc. System and method of pivoted stent deployment
US8663309B2 (en) 2007-09-26 2014-03-04 Trivascular, Inc. Asymmetric stent apparatus and method
JP2010540190A (ja) 2007-10-04 2010-12-24 トリバスキュラー・インコーポレイテッド 低プロファイル経皮的送達のためのモジュラー式血管グラフト
WO2009064697A2 (en) * 2007-11-13 2009-05-22 Boston Scientific Scimed, Inc. Combination coil and liquid embolic for embolization
US8328861B2 (en) 2007-11-16 2012-12-11 Trivascular, Inc. Delivery system and method for bifurcated graft
US8083789B2 (en) 2007-11-16 2011-12-27 Trivascular, Inc. Securement assembly and method for expandable endovascular device
EP2062920A3 (de) 2007-11-21 2009-06-17 Peter Hornbeck Proteinphosphorylation durch basophilische Serin-/Threonin-Kinasen in Insulinsignalisierungspfaden
US20090220991A1 (en) * 2008-02-29 2009-09-03 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
US8591921B2 (en) * 2008-04-10 2013-11-26 Virginia Commonwealth University Induction of tumor hypoxia for cancer therapy
US8246876B2 (en) * 2008-08-18 2012-08-21 Cook Medical Technologies Llc Embolization particles and method for making same
US20100099696A1 (en) * 2008-10-16 2010-04-22 Anthony Edward Soscia Tamper resistant oral dosage forms containing an embolizing agent
WO2010062678A2 (en) * 2008-10-30 2010-06-03 David Liu Micro-spherical porous biocompatible scaffolds and methods and apparatus for fabricating same
CN101536986B (zh) * 2009-04-16 2011-05-04 北京圣医耀科技发展有限责任公司 含索拉非尼的海藻酸钠靶向缓释微球血管栓塞剂及其制备和应用
DE102009051575A1 (de) * 2009-10-26 2011-04-28 NMI Naturwissenschaftliches und Medizinisches Institut an der Universität Tübingen Verwendung von biokompatiblen Zusammensetzungen und hieraus polymerisierten Materialien zur Inhibierung der Angiogenese
US8871873B2 (en) 2011-03-30 2014-10-28 Toray Industries, Inc. Biodegradable particle, vascular embolization material and method for producing biodegradable particles
CA2866281C (en) 2012-03-28 2016-11-01 Toray Industries, Inc. Biodegradable material and method for producing biodegradable material
CN104203299B (zh) 2012-03-28 2016-08-17 东丽株式会社 生物降解性材料以及生物降解性材料的制造方法
CN104411332B (zh) 2012-03-30 2018-11-23 索伦托治疗有限公司 与vegfr2结合的全人抗体
US8992595B2 (en) 2012-04-04 2015-03-31 Trivascular, Inc. Durable stent graft with tapered struts and stable delivery methods and devices
US9498363B2 (en) 2012-04-06 2016-11-22 Trivascular, Inc. Delivery catheter for endovascular device
JP6208749B2 (ja) 2012-05-24 2017-10-04 バイオスフィア メディカル，インコーポレイテッド 薬剤溶出性で磁気共鳴画像法で検出可能な血管閉塞用インプラントとしての使用に適した生体材料
EP3046539A1 (de) * 2013-09-16 2016-07-27 Biocompatibles UK Limited Ölige zusammensetzungen
RU2613888C1 (ru) * 2016-02-26 2017-03-21 государственное бюджетное учреждение здравоохранения "Санкт-Петербургский клинический научно-практический центр специализированных видов медицинской помощи (онкологический)" Способ предоперационного лечения больных с местно-распространенным раком шейки матки T1b2-T2b стадии
RU2619341C1 (ru) * 2016-08-29 2017-05-15 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ коррекции гормонального статуса при посткастрационном синдроме у больных раком шейки матки репродуктивного возраста
WO2018058125A1 (en) 2016-09-26 2018-03-29 Ensemble Group Holdings Methods of assessing and treating cancer in subjects having dysregulated lymphatic systems
US11123453B2 (en) 2018-02-21 2021-09-21 Shinshu University Liquid embolic agent composition
JP7198529B2 (ja) * 2018-11-30 2023-01-04 ネクストバイオメディカル カンパニー リミテッド 生分解性高分子を含む化学塞栓用水和ゲル粒子

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE420565B (sv) * 1974-06-06 1981-10-19 Pharmacia Ab Hjelpmedel for intravaskuler administraring for anvendning i samband med intravaskuler administrering av en losning eller en suspension av ett diagnostiseringsmedel
EP0086627B1 (de) * 1982-02-12 1985-08-28 Unitika Ltd. Antikrebsmittel
US4795741A (en) * 1987-05-06 1989-01-03 Biomatrix, Inc. Compositions for therapeutic percutaneous embolization and the use thereof
DE68910138T2 (de) * 1988-01-19 1994-04-28 Takeda Chemical Industries Ltd Fumagillin als angiostatisches Mittel.
KR0138530B1 (ko) * 1988-09-01 1998-05-15 우메모또 요시마사 푸마길롤 유도체
EP0357061B1 (de) * 1988-09-01 1994-06-08 Takeda Chemical Industries, Ltd. Angiogenese hemmendes Mittel
ATE97410T1 (de) * 1989-03-06 1993-12-15 Takeda Chemical Industries Ltd 6-amino-6-desoxyfumagillole, ihre herstellung und ihre verwendung.
EP0415294A3 (en) * 1989-08-31 1991-06-12 Takeda Chemical Industries, Ltd. Cyclohexanol derivatives, production and use thereof

Also Published As

Publication number Publication date
EP0470569A1 (de) 1992-02-12
EP0470569B1 (de) 1995-11-22
ATE130517T1 (de) 1995-12-15
JP2001039869A (ja) 2001-02-13
CA2048544C (en) 2002-01-01
CA2048544A1 (en) 1992-02-09
DE69114782D1 (de) 1996-01-04
US5202352A (en) 1993-04-13

Similar Documents

Publication Publication Date Title
DE69114782T2 (de) Intravaskulär embolisierendes Mittel mit Gehalt an einem die Angiogenesis hemmenden Stoff.
AP9600794A0 (en) Pharmaceutical compositions containing novel compounds and their use in treating allergic and inflammatory diseases
FI935306A (fi) Puhdistettujen, pintaa modifioivien aineiden käyttö estämään hiukkasten kasautumista steriloinnin aikana
ES2116376T3 (es) Conjugados peg-interferon.
ATE184789T1 (de) Verwendung von carnosolsäure wegen seiner anticarcinogenen und antiviralen eigenschaften
LV12284A (lv) No kudras izdaliti bioaktivi produkti un tos saturosas farmaceitiskas un kosmetiskas kompozicijas
DE69124598D1 (de) Synergistische therapeutische zusammensetzungen und verfahren
DE69434223D1 (de) In der behandlung von il4 auslösenden krankheiten nützliche rekombinante il4 antikörper
ATE154011T1 (de) Inhibitoren der calciumaufnahme
DE69110507T2 (de) Esterderivate von siloxanen und kosmetische Zusammensetzungen die diese Derivate enthalten.
DE68909953T2 (de) Damenbinde und ähnliche objekte mit antiseptischen eigenschaften.
FR2674127B1 (fr) Composition cosmetique pour lutter contre le vieillissement de la peau contenant en association au moins un retinouide et au moins une dialkyl- ou trialkylxanthine.
ATE45286T1 (de) Gammainterferon und lymphotoxin enthaltende synergistische zusammensetzung und ihre herstellung.
IL67940A0 (en) 2,3-diaryl-5-halo-thiophenes,their preparation and pharmaceutical compositions containing them
IT1240683B (it) Composizione farmaceutica contenente egf
IT1199972B (it) Composizioni farmaceutiche per la terapia di sindromi cerebrali involutive e del decadimento mentale
DE69104961D1 (de) Anwendung von Thiazolylalkoxyacrylaten in der Herstellung von Insektiziden und/oder Akanizide-Zusammensetzungen.
AU9034291A (en) Derivates of the human parathormone fragment (1-37) in the amide or ethylamide form as active substance
BR9304405A (pt) Composição contendo carbonila
IE900460L (en) Pharmaceutical composition
DE3176311D1 (en) Substituted 2-hydroxyphenyl cycloalkanes and pharmaceutical compositions thereof
DK44184D0 (da) Kosmetik
BR9006458A (pt) Combinacao fungicida de efeito sinergico e composicao fungicida
KR920005980A (ko) 팽창선 병변의 예방 및 이의 크기를 감소시키기 위한 약제학적 조성물
ATE103814T1 (de) Pharmazeutische zusammensetzungen und deren verwendung in der behandlung von entzuendungen.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: TAKEDA PHARMACEUTICAL CO. LTD., OSAKA, JP

8339 Ceased/non-payment of the annual fee